News

Singapore
Parkway Pantai Introduces Precision Medicine to Customise Treatment Plans For Cancer Patients
October. 9, 2017.
  • Patients to benefit from precision medicine and more accurate diagnostics in Parkway Pantai’s hospitals across Asia
  • Acquired precision medicine platform through 55 per cent stake in Angsana Holdings

 

 

Cancer patients at Parkway Pantai’s hospitals in Singapore can now benefit from personalised treatment plans and more accurate diagnostics with the help of cancer genomics testing.

 

Through Next Generating Sequencing (NGS) which can retrieve more comprehensive genetic information from tumour tissue, doctors are able to determine which drugs are more effective for the patients.

 

Parkway Pantai is the only private healthcare provider in Singapore with in-house precision medicine capability. It brought precision medicine into its integrated suite of healthcare solutions, after buying a 55 per cent stake in Angsana Holdings Pte Ltd for a total consideration of S$9.3 million. The transaction which took place on 31 July further strengthens Parkway Pantai’s leading position as a global healthcare provider.

 

“With Angsana Molecular and Diagnostics, we now have the molecular capabilities to customise medical treatment for each individual patient. Precision medicine enables doctors and patients to make better informed decisions on how to manage diseases more efficiently and safely,” says Dr Tan See Leng, Group Chief Executive Officer and Managing Director of Parkway Pantai.

 

Angsana operates two College of American Pathologists (CAP) accredited laboratories in Singapore and Hong Kong. Its key products include Non Invasive Prenatal Testing (NIPT), allergy testing and cancer genomics.

 

“We are committed to deliver high-performance and affordable molecular diagnostic services to tailor treatment to the needs and characteristics of individual patients,” says Dr Chris Tan, Chief Executive Officer and founder of Angsana Molecular & Diagnostics. “We are excited to work with Parkway Pantai’s vast network of healthcare facilities to meet the health demand of the Asian population.”

 

Plans are being formalised for Parkway Pantai’s 14 hospitals in Malaysia to perform NIPT, in a collaboration between Pantai Premier Pathology and Angsana. NIPT – a molecular test which detects chromosomal abnormalities such as Trisomy 21 in the fetus through a simple blood-draw from the mother – will also be offered at Parkway Pantai’s 10 hospitals and medical centres in India.

 

About Parkway Pantai

Parkway Pantai is one of Asia’s largest integrated private healthcare groups operating in Singapore, Malaysia, India, China, Brunei and United Arab Emirates. For over 40 years, its Mount Elizabeth, Gleneagles, Pantai and Parkway brands have established themselves as the region’s best known brands in private healthcare, synonymous with best-in-class patient experience and outcomes.

 

Leveraging its global track record for medical excellence and managing world-class hospitals, Parkway Pantai is committed to making a difference in people’s lives through excellent patient care, steadily expanding its reach in markets where demand for quality care is strong and growing.

 

Parkway Pantai is a leading healthcare player in its home markets of Singapore, Malaysia and India and key growth markets of China and Hong Kong.

 

It is part of IHH Healthcare, one of the world’s largest healthcare groups by market capitalisation. IHH operates more than 10,000 licensed beds across 50 hospitals in 10 countries worldwide, offering the full spectrum of integrated healthcare services from clinics to hospitals to quaternary care and a wide range of ancillary services including medical education.

 

In Singapore, Parkway Pantai is the largest private healthcare operator with four JCI-accredited, multi-specialty tertiary hospitals – Mount Elizabeth Hospital, Mount Elizabeth Novena Hospital, Gleneagles Hospital and Parkway East Hospital. It also owns ParkwayShenton, a large network of primary healthcare clinics and services, ParkwayHealth Radiology, ParkwayHealth Laboratory and Parkway College.

 

In Malaysia, Parkway Pantai is the second largest private healthcare provider operating ten Pantai Hospitals, four Gleneagles Hospitals and ancillary healthcare services including Pantai Integrated Rehab and Pantai Premier Pathology.

 

India is now its third home market following the acquisition of Continental and Global Hospitals in 2015. Today, Parkway Pantai has a network of 7 hospitals and 3 medical centres in the key cities of Chennai, Bengaluru, Hyderabad, Kolkata and Mumbai.

 

Parkway Pantai also has more than 20 patient assistance centres across the globe, providing patients with seamless patient care and a one-stop referral source to its hospitals and services.

 

For more information, please visit www.parkwaypantai.com.

 

About Angsana Molecular & Diagnostics

Angsana Molecular & Diagnostics specialises in developing premium molecular diagnostic assays, serving the following four medical areas that have the largest impact in Asian population: allergy and molecular allergology, fetal maternal health, molecular oncology and pharmacogenetics.

 

Through analysis of medical conditions at a molecular level, combined with clinical consultation by board-certified medical geneticists and sub-specialty trained pathologists, Angsana empowers clinicians and patients to make better informed clinical decisions and improve the quality of patient care.

 

Strategically located in Asia with multi-laboratory operations in Singapore, Hong Kong and Malaysia, Angsana Molecular & Diagnostics is dedicated to serving the Asian community with fast and more affordable services within easy reach.

 

For more information, visit www.angsanadx.com.

 

CONTACT

Lim Bee Ling

Group Corporate Communications

Parkway Pantai

+65 9724 5664

[email protected]

Share
Singapore
Counsyl and Angsana Bring Expanded Carrier Screening to Clinicians and Patients in Hong Kong – Agreement Expands Global Access to Genetic Testing for Serious Inherited Conditions
July. 10, 2017.

 

Counsyl, a DNA testing and genetic counseling service, today announced an expanded agreement with Angsana Molecular & Diagnostics Laboratory, a multinational laboratory services company, to commercialize Counsyl’s proprietary expanded carrier screening (ECS) test in Hong Kong, an influential market for advanced medical care throughout Asia.

 

Counsyl’s ECS leads the industry in identifying the approximately one in 65 couples of East Asian descent who are at-risk of passing serious and actionable conditions to their children. This information allows couples to make informed decisions for conditions that can be passed down to children. Angsana’s expansive network of clinicians will now be able to offer this test to their patients. All samples will be processed at Counsyl’s CLIA-certified automated clinical laboratory in South San Francisco, California.

 

To help clinicians learn more about the benefits of offering ECS to patients, Angsana and Counsyl will host two joint events for physicians on July 11 and 13 at Central and Tsimshatsui, Hong Kong. The sessions will feature presentations and discussion sessions with Mr. Kenny Wong, MS, CGC, clinical product director, carrier screening at Counsyl. Both lectures will be chaired by Hong Kong obstetrician & gynecologist specialists in reproductive medicine and will be accredited Continuing Medical Education (CME) points by the Hong Kong College of Obstetricians & Gynaecologists (HKCOG).

 

“This expansion is part of our larger strategic effort to increase global access to comprehensive, clinically relevant and affordable testing in women’s health,” stated Matthew J. Meyer, Counsyl’s senior vice president of corporate development. “Angsana’s extensive clinical partnerships in Hong Kong will help to quickly bring Counsyl’s industry-leading expanded carrier screening offering to a new patient population.”

 

“Angsana, which operates two College of American Pathologists (CAP) accredited laboratories in Singapore and Hong Kong, is most committed to improving healthcare through utilization of molecular information to tailor treatment to the needs and characteristics of individual patients,” says Dr. Chris Tan, chief executive officer and founder of Angsana Molecular & Diagnostics. “We chose Counsyl’s panel because of its coverage of serious, clinically actionable and prevalent diseases, which is aligned to our mission of empowering doctors and patients in making better informed decisions.”

 

About Angsana Molecular & Diagnostics Laboratory

Angsana Molecular & Diagnostics Laboratory specializes in developing premium molecular diagnostic assays, serving the following four medical areas that have the largest impact in Asian population: allergy and molecular allergology, fetal maternal health, molecular oncology and pharmacogenetics. Through analysis of medical conditions at a molecular level, combined with clinical consultation by board-certified medical geneticists and sub-specialty trained pathologists, Angsana empowers clinicians and patients to make better informed clinical decisions and improve the quality of patient care. Strategically located in the center of Asia with multi-laboratory operations in Singapore, Hong Kong and Malaysia, Angsana Molecular & Diagnostics Laboratory is dedicated to serving the Asian community with fast and more affordable services within easy reach. For more information, visit www.angsanadx.com.

 

About Counsyl

Counsyl is a DNA testing and genetic counseling service committed to helping patients understand their DNA and how it can inform important health decisions. Whether it’s starting a family or evaluating risk for cancer, Counsyl’s DNA tests provide patients with early awareness about genetic conditions, so they can live informed and prepare for the future. Counsyl has screened more than 750,000 patients and served more than 10,000 healthcare professionals. For more information, visit www.counsyl.com. Sign up for news announcements from Counsyl at subscribe.counsyl.com.

 

CONTACT:

Counsyl

Donelle M. Gregory

[email protected]

 

Angsana Molecular & Diagnostics Laboratory (HK) Ltd

Clara Fu

+852 9713 2787

[email protected]

Share
Singapore
Angsana’s RNA-based fusions cancer panel selected for Ignyta’s STARTRK2 clinical trial in Asia-Pacific
Mar. 03, 2017.

Angsana Molecular & Diagnostics has announced today that it will be a partner molecular test lab for STARTRK-2 clinical trial sites in Asia working with Ignyta, Inc., (NASDAQ: RXDX), a biotechnology company focused on precision medicine in oncology. Angsana Molecular & Diagnostics’ fusion cancer panel will be used for screening TRK, ROS1 and ALK fusions in the STARTRK-2 clinical trial, a registration-enabling global Phase 2 basket clinical trial for entrectinib, Ignyta’s investigational, orally available, CNS-active tyrosine kinase inhibitor targeting tumors that harbor TRK, ROS1 or ALK fusions.

 

Phase 1 data recently published online in Cancer Discovery showed entrectinib to be well tolerated, with responses observed in non-small cell lung cancer (NSCLC), colorectal cancer, mammary analog secretory carcinoma (MASC), melanoma and renal cell carcinoma as early as four weeks after first treatment and lasting as long as 2.5 years and still ongoing. That publication reported a 79% response rate in 24 patients with TRK, ROS1, or ALK-driven extracranial solid tumors, and showed entrectinib responses to be both rapid and durable in patients with advanced solid tumors across multiple histologies and each of the molecular targets of interest, including in multiple patients with metastatic CNS disease.

 

“Ignyta is excited to partner with Angsana to conduct diagnostic screening at our STARTRK-2 clinical trial sites in Asia, which will help us get entrectinib to patients with tumors driven by TRK, ROS1 or ALK fusions,” said Jonathan Lim, M.D., Chairman and CEO of Ignyta. “Entrectinib is the only TRK inhibitor to have published data demonstrating RECIST responses in NSCLC and in patients with cancer in the CNS. The anti-tumor activity seen across cancer types and entrectinib’s ability to treat bulky CNS disease, particularly important given the propensity for many solid tumors to metastasize to the brain, is extremely encouraging,” continued Dr. Lim.

 

“The era of the shift away from one-size-fits-all, trial-and-error medicine and toward a health care system that utilizes molecular information to improve outcomes and make the health care system more efficient has finally arrived to Asia Pacific especially in the area of targeted therapy in oncology,” says Dr Chris Tan, Chief Executive Officer and founder of Angsana Molecular & Diagnostics. Dr Chris Tan added that our CAP accredited molecular lab, turnaround time and cost efficiency is critical to support Ignyta for their STARTRK-2 trial in Singapore and Asia.

About Angsana Molecular & Diagnostics Laboratory

Angsana Molecular & Diagnostics Laboratory specializes in developing premium molecular diagnostic assays, serving the following four medical areas that have the largest impact in Asian population: allergy and molecular allergology, fetal maternal health, molecular oncology and pharmacogenetics. Through analysis of medical conditions at a molecular level, combined with clinical consultation by board-certified medical geneticists and sub-specialty trained pathologists, Angsana empowers clinicians and patients to make better informed clinical decisions and improve the quality of patient care. Strategically located in the center of Asia with multi-laboratory operations in Singapore, Hong Kong and Malaysia, Angsana Molecular & Diagnostics Laboratory is dedicated to serving the Asian community with fast and more affordable services within easy reach. For more information, visit www.angsanadx.com.

 

About Ignyta, Inc.

Blazing a New Future for Patients with Cancer™

 

At Ignyta, we work tirelessly on behalf of patients with cancer to offer potentially life-saving, precisely targeted therapeutics (Rx) guided by companion diagnostic (Dx) tests. Our integrated Rx/Dx strategy allows us to enter uncharted territory, illuminating the molecular drivers of cancer and quickly advancing treatments to address them. This approach embraces even those patients with the rarest cancers, who have the highest unmet need and who may otherwise not have access to effective treatment options. With our pipeline of potentially first-in-class or best-in-class precision medicines, we are pursuing the ultimate goal of not just shrinking tumors, but eradicating cancer relapse and recurrence in precisely defined patient populations. For more information, please visit: www.ignyta.com.

 

CONTACT:

Angsana Molecular & Diagnostics Laboratory Pte Ltd
Gerard Yeong
[email protected]

Share
Singapore
EUROIMMUN (SEA) Partners with Angsana Molecular & Diagnostics on Allergy Diagnostics and Testing in Singapore
Nov. 22, 2016.

EUROIMMUN (SEA) and Angsana Molecular & Diagnostics today build a strategic partnership on the allergy diagnostics and testing to support clinicians, hospitals and private laboratories in South East Asia. This collaboration helps to bring the diagnostics and patient care synergies towards a better clinical management of patients with suspected allergies. Under the strategic collaboration, Angsana Molecular & Diagnostics would offer the comprehensive analysis of sensitizations against inhalation, food and other allergens to provide the precise determination of allergen. EUROIMMUN is committed with the customized two Allergy profiles to be well suited and cater to the region.

 

“There is a need for greater understanding on the risk of true poly-sensitizations for better patient management. With the simultaneous multi-parameter screening, the cooperation with EUROIMMUN gives us perfect position to take lead in allergy diagnostics and testing in the SEA region.” says Dr Chris Tan, Chief Executive Officer and founder of Angsana Molecular & Diagnostics. Dr Chris Tan added that “This partnership enables us to combine cost effective and accurate health screening providing an expanded, high-quality diagnostics service under the CAP-accredited environment”.

 

 

The significance of this cooperation and contribution from both partners are recognized by Li Chuan, President of APAC Group and Managing Director of EUROIMMUN (SEA) Pte Ltd. “Our collaboration with Angsana Diagnostics will provide a precise determination for Allergy diagnostics to benefit the patients with suspected allergies. Furthermore, EUROIMMUN is committed to promote and focus on the use of allergy testing via EUROIMMUN Academy as continuous medical education to the clinicians and others.”

 

 

As a leading company in medical diagnostics, the cooperation between EUROIMMUN and Angsana Molecular & Diagnostics will play an important role in promoting the importance of diagnostics in the Asia Pacific region. Chief Executive Officer and Founder of EUROIMMUN Medizinische Labordiagnostika AG, Prof. Dr. Winfried Stöcker emphasized that “Asia Pacific region has been one of the important market for EUROIMMUN and we will continue to support the diagnostics market growth and development in Asia and EUROIMMUN, will and strive to enhance our collaboration with clinicians, medical providers to improve health outcomes and provide precise patient management.”

 

About Angsana Molecular & Diagnostics Laboratory

Angsana Molecular & Diagnostics Laboratory specializes in developing premium molecular diagnostic assays, serving the following four medical areas that have the largest impact in Asian population: allergy and molecular allergology, fetal maternal health, molecular oncology and pharmacogenetics. Through analysis of medical conditions at a molecular level, combined with clinical consultation by board-certified medical geneticists and sub-specialty trained pathologists, Angsana empowers clinicians and patients to make better informed clinical decisions and improve the quality of patient care. Strategically located in the center of Asia with multi-laboratory operations in Singapore, Hong Kong and Malaysia, Angsana Molecular & Diagnostics Laboratory is dedicated to serving the Asian community with fast and more affordable services within easy reach. For more information, visit www.angsanadx.com.

 

About EUROIMMUN

EUROIMMUN was founded in 1987 and has its headquarters in Lübeck, Germany. It is committed to develop, produce and sell test systems for the diagnosis of diseases, and software and automation solutions for the performance and evaluation of these assays. So far laboratories in about 200 countries use EUROIMMUN products for the diagnosis of autoimmune, infectious diseases and allergies, and to perform genetic analyses. The company is based on worldwide-patented state-of-the-art production methods and microanalysis techniques and is one of the world’s leading manufacturers of medical laboratory diagnostics. The company’s reference laboratory is unequalled in the whole field of autoimmune diagnostics. With their quality and standardization, EUROIMMUN products are conquering the leading position in medical diagnostics worldwide. For more information, visit http://www.euroimmun.com.

 

CONTACT:

Angsana Molecular & Diagnostics Laboratory Pte Ltd
Clara Fu
+852 2793 0782
[email protected]

Share
Singapore
Angsana Provides Tests for Allergen Sensitization Specific for Asian Population
Nov. 1, 2016.

Angsana Molecular & Diagnostics Laboratory today announced that it will provide tests for allergen sensitization specific for the Asian population using industry leading technology by Thermo Fisher Scientific. The tests will be based on Thermo Fisher’s ImmunoCAP technology and performed on Phadia Laboratory Systems.

 

Allergy constitutes a major health concern in both adolescents and adults. While many allergens are common across populations, there has been increased recognition of differences in the prevalence and morbidity of atopic diseases among different ethnic groups and across different geographic regions. Factors such as genetics, environmental exposure, diet and social behavior appear to contribute.

 

Angsana is seeking to define and validate specific tests for allergen sensitization that are suited to local needs. ImmunoCAP technology is well known for its high specificity and sensitivity, quantitative results, high quality and a comprehensive menu of allergens and allergen components. ”

 

Angsana is committed to deliver high-performance and affordable molecular diagnostic services to meet the health demand of Asian population. We are excited to work with Thermo Fisher and its technology to help us expand our service capabilities to better address this major public health concern,” said Dr. Chris Tan, Chief Executive Officer of Angsana. “With the rising incidence of atopic diseases, particularly among younger children, it is important to better understand the regional and ethnic differences in Asian countries,” said Dr. Richard Choy, Angsana’s Chief Scientific Officer and managing director of Angsana Hong Kong laboratory. “Through collaboration with local medical experts and healthcare providers, Angsana aims to provide a testing solution for Asia, in order to help improve the diagnosis efficiency and aid better allergy management.”

 

“We’re pleased that Angsana recognizes our quality and expertise and we are pleased that our technology can be used to support their efforts,” said [Stefan Wolf], president, ImmunoDiagnostics, Thermo Fisher. “Providing tests for allergen sensitization for the Asian population will help to enable healthcare professionals to have a better understanding of the symptoms of their patients.”

 

Angsana has recently acquired Allergy Laboratory, a Singapore-based private laboratory with over 10-year experience serving in the allergy testing business. “The acquisition enables us to combine the existing tests and dedicated expertise from Allergy Laboratory with the range of premium molecular assays from Angsana, providing an expanded, high-quality diagnostic services under the CAP-accredited environment” said Dr. Chris Tan from Angsana.

 

About Angsana Molecular & Diagnostics Laboratory

Angsana Molecular & Diagnostics Laboratory specializes in developing premium molecular diagnostic assays, serving the following four medical areas that have the largest impact in Asian population: allergy and molecular allergology, fetal maternal health, molecular oncology and pharmacogenetics. Through analysis of medical conditions at a molecular level, combined with clinical consultation by board-certified medical geneticists and sub-specialty trained pathologists, Angsana empowers clinicians and patients to make better informed clinical decisions and improve the quality of patient care. Strategically located in the center of Asia with multi-laboratory operations in Singapore, Hong Kong and Malaysia, Angsana Molecular & Diagnostics Laboratory is dedicated to serving the Asian community with fast and more affordable services within easy reach. For more information, visit www.angsanadx.com.

 

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of $17 billion and more than 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support.

 

CONTACT:

Angsana Molecular & Diagnostics Laboratory Pte Ltd
Clara Fu
+852 2793 0782
[email protected]

Share
Singapore
Agilent Technologies Provides Tools to Angsana to Develop Molecular Assays to Improve Fetal and Maternal Health in Asian Population
Oct. 7, 2015.

Agilent Technologies Inc. (NYSE: A) today announced that it will provide genomic tools to Angsana Molecular & Diagnostics Laboratory, a multisite molecular diagnostics service provider headquartered in Singapore, to supply genomics products to enable Angsana to develop new genomics-based assays that are customized to fit the Asian population.

 

This collaboration enables Angsana to develop molecular diagnostics to create new solutions focused on fetal and maternal health.

 

To develop the assays, Angsana will use a range of Agilent technologies, including DNA microarrays, target enrichment platforms, DNA/RNA quality control tools, automated liquid handling, and probes that incorporate fluorescence in situ hybridization, or FISH, a technique used to detect the presence of specific DNA sequences.

 

“Agilent’s cutting-edge genomics technology enables precise identification of genetic changes,” said Russell McInnes, Agilent’s director of sales for genomics in the Southern Asia Pacific and Korea. “We are delighted to partner with Angsana as they develop new molecular assays relevant to local populations.”

 

“Angsana aims to be a life care company committed to better health care through providing trusted and high-quality molecular diagnostics services to the regional health-care network in Asia,” said Dr. Chris Tan, chief executive of Angsana. “Partnership with Agilent allows us to capture the best offered by the technology and to stay ahead of the competition.”

 

“About 2 to 3 percent of babies are born with some type of birth defect, many of which are due to chromosomal abnormalities,” said Dr. Richard Choy, Angsana’s chief scientific officer and managing director of the CAP-accredited Angsana Hong Kong Laboratory. “Technologies like the microarrays and target enrichment-based sequencing offered by Agilent provide the means to enable us to analyze genetic information in a fast, accurate and cost-effective manner. Through close collaboration with local maternal and fetal specialists, Angsana will be able to develop customized molecular assays validated for diagnosing chromosomal abnormalities in a fetus, providing expectant parents with a higher level of assurance.”

 

About Angsana Molecular & Diagnostics Laboratory

Angsana Molecular & Diagnostics Laboratory specializes in developing premium molecular diagnostic assays, serving the following four medical areas that have the largest impact in Asian population: allergy and molecular allergology, fetal maternal health, molecular oncology and pharmacogenetics. Through analysis of medical conditions at a molecular level, combined with clinical consultation by board-certified medical geneticists and sub-specialty trained pathologists, Angsana empowers clinicians and patients to make better informed clinical decisions and improve the quality of patient care. Strategically located in the center of Asia with multi-laboratory operations in Singapore, Hong Kong and Malaysia, Angsana Molecular & Diagnostics Laboratory is dedicated to serving the Asian community with fast and more affordable services within easy reach. For more information, visit www.angsanadx.com.

 

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A), a global leader in life sciences, diagnostics and applied chemical markets, is the premier laboratory partner for a better world. Agilent works with customers in more than 100 countries, providing instruments, software, services and consumables for the entire laboratory workflow. The company generated revenues of $4.0 billion in fiscal 2014 and employs about 12,000 people worldwide. Agilent marks its 50th anniversary in analytical instrumentation this year. Information about Agilent is available at www.agilent.com.

 

CONTACT:

Angsana Molecular & Diagnostics Laboratory Pte Ltd
Hailing Sun
+65-6873-9959
[email protected]

 

Agilent Technologies Inc.
Victoria Wadsworth-Hansen
+1 408-553-2005
[email protected]

Share
Singapore
Establishment of Angsana Molecular & Diagnostics Pte Ltd
June 2014

MORE

Establishment of Angsana Molecular & Diagnostics Pte Ltd – a life care company committed to better healthcare for humanity’s tomorrow. Our headquarters is in Singapore with two other offices in Hong Kong and Malaysia. We specialize in developing premium genomic assays in four areas that have the largest impact on the Asian population – Molecular Oncology, Fetal Maternal Health, Allergy & Molecular Allergology as well as Pharmacogenomics.

Founded by a unique, diversified team of leading Asian Clinical Scientists, prominent Healthcare Leaders and Business Directors, we not only provide clinicians with the analysis of medical conditions at a molecular level but also consultation on the diagnosis.

 

To stay ahead in the field of molecular & diagnostics, we are backed by a world class Scientific Advisory Board comprising Medical and Clinical Geneticists from the US and Asia to help formulate our scientific research strategies as well as a research and development team with expertise in advanced genomic technologies and bioinformatics.

 

Partnerships with leading pharmaceutical and biotechnology companies as well as academic institutions in Asia and the US give us unique access to state-of-the-art technology and knowledge in molecular diagnostics.

 

We use advanced technology platforms such as Next-generation Sequencing, Microarray Platforms, Sanger Sequencing, Digital PCR and Real-time PCR, Karyotyping and FISH and Phadia Laboratory System, to generate genomic data that is then analysed by an established bioinformatics analysis system and seamlessly communicated to clinicians and patients through a secured Lab Information System via an online web portal.

 

With CAP accreditation and ISO 15189 certifications for laboratory facilities, we will be able to ensure the highest standards of service trusted by clinicians and patients.

 

singapore

Share